Related Experiment Video
Updated: Aug 8, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
The association of 6-minute walk performance and outcomes in stable outpatients with heart failure
Jeptha P Curtis1, Saif S Rathore, Yongfei Wang
1Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8088, USA.
Insights
The 6-minute walk test is a valuable tool for predicting mortality risk in heart failure patients. Walking less than 200 meters indicates a significantly higher risk of death, aiding in patient stratification.
Area of Science:
- Cardiology
- Clinical Medicine
- Exercise Physiology
Background:
- The 6-minute walk test (6MWT) is frequently used in clinical practice.
- Its prognostic value in stable outpatients with heart failure requires further evaluation.
Purpose of the Study:
- To assess the prognostic significance of the 6-minute walk test distance in stable heart failure outpatients.
- To determine if 6MWT distance can predict mortality and heart failure-related death.
Main Methods:
- Analysis of 541 patients from the Digitalis Investigation Group trial.
- Patients categorized by 6MWT distance: <=200 m, 201-300 m, 301-400 m, and >400 m.
- Median follow-up of 32 months, assessing all-cause mortality and heart failure-specific death.
Main Results:
- Patients walking <=200 m had significantly higher all-cause mortality (43.9%) compared to those walking >200 m (23.3%, P<0.001).
- Mortality rates were similar for patients walking >200 m (23.7% to 19.8%, P for trend 0.45).
- Distance <=200 m was associated with increased mortality (HR 1.47) and death from worsening heart failure (HR 2.89) in multivariable analysis.
Conclusions:
- The 6-minute walk test effectively identifies patients walking <=200 m as having a markedly increased risk of death.
- Standardizing the 6-minute walk test to a time- and distance-based protocol could enhance its efficiency while preserving prognostic information.
Background:
We sought to evaluate the prognostic value of the 6-minute walk test in stable outpatients with heart failure.
Methods And Results:
We examined the association of 6-minute walk test distance and outcomes among 541 patients enrolled in the Digitalis Investigation Group trial. Patients were grouped by total distance (< or =200 m, 201 m-300 m, 301 m-400 m, and >400 m) with median follow-up of 32 months. All-cause mortality for patients who walked < or =200 m was significantly higher than patients who walked >200 m (43.9% versus 23.3%, P<0.001), but mortality was comparable among patients who walked >200 m (201 m-300 m: 23.7%, 301 m-400 m: 25.2%, >400 m 19.8%, P for trend 0.45). Results were similar for death due to worsening heart failure (< or =200 m: 29.3%, 201 m-300 m: 7.6%, 301 m-400 m: 6.7%, >400 m: 6.1%, P for trend <0.001). In multivariable analysis, distance < or =200 m remained associated with increased mortality (< or =200 m: hazard ratio (HR) 1.47, 95% CI 0.96-2.27; >200 m: HR 1.00, Referent; P=0.07) and death due to worsening heart failure (< or =200 m: HR 2.89, 95% CI 1.54-5.41; >200 m: 1.00, Referent; P=0.001).
Conclusions:
The 6-minute walk test identifies patients who walk less than 200 m as being at markedly increased risk of death. Changing the 6-minute walk test to a time- and distance-based standard would improve the efficiency of the test while retaining the bulk of the prognostic information.
Related Concept Videos
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Cardiomyopathy VI: Nursing Management

